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biomimetic stage-specific diabetic wound
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Here, an oxidation/acid dual-responsive nanohybrids/ark system
was produced. The microfluidics-produced nanohybrids endow the
system with an orchestrated cascade from wound detection, reactive
oxygen species scavenging, drug release to hydrogel formation. The
drug release behavior imitates the dynamic wound healing process,
thus rendering an enhanced bio-mimetic regeneration.
Intelligent materials that adapt and respond to their environ-
ment are termed as dynamic materials,1 and have recently drawn
attention for tissue engineering and regeneration. Conventional
materials often fail to apprehend the dynamic and hetero-
geneous nature of an in vivo environment during the regeneration
process. In contrast, strategically designed dynamic materials
can bio-mimetically alter their physiochemical properties when
encountering a specific biological irritant, further executing pro-
grammed functions, and thus holding great clinical value.1–4
Diabetic foot ulcer (DFU) is a critical non-healing complication
for diabetic patients.5 Over the past decades, great efforts have
been made to overcome this challenge. However, despite the
reporting of several bioactive substances (e.g., small molecule
drugs, growth factors, and cytokines) used to accelerate the
healing process, the combination of a ‘‘smart’’ delivery system
and tailored release behavior is equally indispensable. As for
tissue engineering, long-term or un-regulated drug delivery may
cause aberrant regeneration and even formation of carcinoma-like
structure.6,7 Inspired by the meticulous self-regulating system
within the human body, where regenerative enhancement is
dynamically altered during different healing stages,8–10 prospec-
tive materials for fabricating the envisioned bio-mimetic delivery
system should be able to sense and respond to the healing
process, and concurrently alter their drug releasing behavior.
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We have developed here a self-regulated dynamic nanohybrid that can
sensitively respond to a hyperglycemic microenvironment. The nanohybrid
is subsequently embedded in a collagen patch for further in vivo diabetic
wound healing applications. The nanohybrid with a core/shell structure was
produced through a single-step microfluidics-assisted nanoprecipitation
method, where drug-loaded porous silicon (PSi) nanoparticles were
encapsulated by a H2O2 responsive polymer, 4-(hydroxymethyl)-phenyl-
boronic acid pinacol ester conjugated with oxidized dextran (POD). POD
encapsulation can effectively block accessible pores of PSi, thus preventing
a potent burst release of the drug. Upon exposure to high levels of glucose,
GOx can initiate glucose oxidation, generating gluconic acid and H2O2.
Then, POD can consume the produced H2O2 to undergo degradation and
further release the encapsulated drug. The degradation product of POD,
oxidized dextran (ODEX), can in situ form a hydrogel with the collagen
patch. This in situ nanoparticle/hydrogel transformation creates a moist
environment around the wound bed, altering the stiffness of the patch to
better mimic elastic properties of the natural soft tissues. Glucose content
within the wound bed also gradually decreased as a result of less bleeding
and interstitial fluid exudation, thus a stage/temporal-specific drug release
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Phenylboronic acid ester (PAE) is an important building block
for constructing a series of oxidation responsive materials.11–14
This unique feature renders it suitable for application in chronic
wounds due to elevated concentrations of common reactive
oxygen species (ROS) within the wound bed.11 However, despite
PAE’s ROS scavenging profile and boronate degradation pro-
ducts, which favor augmentation of the wound healing rate, few
papers have applied PAE based materials for DFU caring.15,16
This may be explained by selective oxidation behavior of PAE,
which can only be oxidized by H2O2 and not by other ROS,
such as superoxide, hypochlorous acid or hydroxyl radical17,18 –
resulting in a sensitivity concern when applied in vivo. The low
solubility of PAE containing polymers in various solvents further
constrains the productions of its electrospun nanofibrous
membrane or hydrogels.13 Therefore, a more deliberately designed
system should be conceived for further applications.
High level of glucose is another pivotal factor in diabetes and
may impact the delivery system construction for DFU repair.
Among the reported glucose responsive materials so far, the
introduction of glucose oxidase (GOx) is especially advantageous
for diabetic wound healing, as it can effectively decrease the
glucose level that is likely of great importance for diabetic
wound healing management.19,20 However, GOx-containing
bulk hydrogels exhibit an insensitive response to glucose.21,22
GOx-Containing membranes suffer from low mechanical strength,
which can result in premature leakage of the drug.21,22 Moreover,
the side products, especially of hydrogen peroxide that is generated
by this oxidation process, may further increase concerns of its
biocompatibility.23,24 A viable approach to circumvent this
issue is to fabricate a closed-loop nanocarrier that can expend
its side products, and sequentially generate the required down-
stream actions.
Based on above considerations, herein, we have developed a
self-regulated dynamic nanohybrid that could sensitively
respond to the hyperglycaemic microenvironment. The nano-
hybrid with a core/shell structure was produced through a
single-step microfluidics-assisted nano-precipitation method,25,26
where drug-loaded porous silicon (PSi) nanoparticles were encap-
sulated by a H2O2/acid dual-responsive polymer formed by
4-(hydroxymethyl)-phenylboronic acid pinacol ester conjugated
with oxidized dextran (POD). PSi has been widely investigated
for biomedical applications due to its biocompatibility and
flexibility in loading different types of cargos.27,28 Moreover,
its main degradation product, orthosilicic acid, has also been
known to favor the cutaneous traumatic healing,29–31 thus
making PSi an attractive candidate for DFU application. POD
encapsulation can effectively block accessible pores of PSi, thus
preventing a potent burst release of the drug. Furthermore, the
redundant aldehyde groups on the outer surface of POD can
both immobilize GOx through the formation of a pH-responsive
dynamic covalent bond (imine),32,33 and/or simultaneously
anchor other amine containing drugs. The benefits of such a
delivery system arise from the interaction between the oxidation/
acid dual-responsive POD and GOx, which confers control over
the drug release property in a glucose concentration dependent
manner. To facilitate in vivo application, the nanohybrids were
feasibly loaded onto a collagen ark. Interestingly, the degrada-
tion product of POD, oxidized dextran (ODEX), could in situ
form a hydrogel with the collagen patch. This in situ nano-
particle/hydrogel transformation can create a moisture environ-
ment around the wound bed, altering the stiffness of the patch
to better mimic the elastic properties of natural soft tissues.34,35
More importantly, along with dermis regeneration and cutaneous
gap closure during the treatment, the glucose content within the
wound bed will gradually decrease as a result of less bleeding and
interstitial fluid exudation – thus, a stage/temporal-specific drug
release schedule can be achieved.36 Herein, the physicochemical
properties of the nanohybrids were characterized, and the
glucose triggered orchestrated cascade and its potent bioactivity
was evaluated both in vitro and in vivo through diabetic wound
mice model.
Fig. 1A schematically illustrates the fabrication and dynamic
transformation of the nanohybrids during the treatment process.
We modified oxidized dextran (ODEX) with phenylboronic
pinacol ester to produce POD. The synthesis procedure and
its degradation under H2O2 irritation is briefly described in
Fig. S1 (ESI†). Successful oxidation of dextran was first con-
firmed by fourier transform infrared spectroscopy (FTIR), as a
new band was observed at 1720 cm1, which was attributed to
the aldehyde groups (Fig. S2, ESI†).37 Oxidation degree was
further determined as 40.2% by 1H NMR by the carbazone
formation method (ESI†). 4-(Hydroxymethyl)phenylboronic
acid pinacol ester (PAPE) was then conjugated to the residue
hydroxyl groups of oxidized dextran via a carbonate linkage.
The substitution degree of hydroxyl groups was ca. 31%, as
determined from the 1H NMR peak area with the peak of
dextran used as the standard (Fig. S3, ESI†).13 The conjugation
of PAPE enhanced the hydrophobicity of polymer, as the new
product precipitated out from an aqueous solution. A micro-
fluidic assisted nanoprecipitation method was used to con-
struct PSi@POD, and the nanoprecipitation process was
triggered by a passive microfluidic mixing in a co-flow glass
capillary microtube.25,38 The outer POD layer within the micro-
tube was formed through nucleation and nanoprecipitation
driven by diffusion and mixing between the solvent (EtOH/
dd-H2O = 8 : 2, v/v) and anti-solvent (dd-H2O) streams across the
interface. It should be noted that no extra surfactant was
needed to obtain particles with satisfactory polydispersity index
(PdI) during this process, as the unmodified hydroxyl groups on
ODEX function as stabilizers.39 Transmission electron micro-
scopy (TEM) images indicated the successful encapsulation
of PSi nanoparticles (Fig. 1B(a)) in the POD matrix. As shown
in Fig. 1B(b), after encapsulation, the irregular shape and the
porous structure of PSi were fully covered and new nanohybrids
with spherical morphology were formed. Energy dispersive
X-ray microscopy (EDX) was carried out to further confirm the
successful encapsulation (Fig. 1B(c)). At physiological condi-
tions, free aldehyde groups on the surface steadily formed
Schiff-bases with primary amine groups,40 which were further
utilized for surface immobilization of both GOx and deferoxamine
(DFO) without causing obvious morphology changes (as observed
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images of the prepared particles embedded in the collagen
patch illustrated a uniformly formed nano-network (Fig. 1B(e)),
confirming it to be a facile method for the preparation of a
topical patch. The successful encapsulation and Schiff-base
formation were verified by FTIR (Fig. 1C). After encapsulation,
the band at 1045 cm1 for Si–O, which is a typical band for PSi,
disappeared, and was replaced by the band at 1010 cm1 due to
polysaccharide encapsulation. The typical band from Schiff-base
(CQN) was observed at 1637 cm1 after DFO conjugation.25,41
After the encapsulation, the particle size changed from
185  2 (PSi) to 226  5 nm (PdI: 0.12  0.01 vs. 0.06  0.03)
and the zeta (z)-potential values shifted from 21.4  0.9 to
48.1  2.0 mV, while after Schiff-base formation both size
(284  7) and PdI (0.26  0.04) increased and the zeta potential
changed to 23.9  1.2 mV due to the surface drug/protein
immobilization (Fig. 1D).
The introduction of GOx in the nanohybrids can endow the
system with an ability to respond to different glucose levels, as
glucose can be catalyzed by GOx to generate gluconic acid and
hydrogen peroxide.42 The glucose-dependent H2O2 generation
and pH-drop were separately confirmed through the 20,7 0-
dichlorodihydrofluorescein diacetate (DCFH-DA) and phenol-
red assisted colorimetric methods (Fig. S4, ESI†). It was noted
that at glucose concentration of 4 mg mL1, which is the typical
glucose level at hyperglycemia, the H2O2 yield was rather high
(380  7 mM). This concentration may bring potent damage to
the surrounding environment when applied for biomedical
applications. We hypothesized that the co-existing POD could
consume H2O2 and initiate the downstream action, therefore
H2O2 induced degradation behavior of PAPE–ODEX was further
investigated. Macroscopic images confirmed the H2O2 triggered
polymer degradation (Fig. 2A(a)). Bare POD particles were
suspended in H2O with different concentrations of H2O2 and
the degradation process was observed by measuring light
scattering at 500 nm (Fig. 2A(b)). The results suggested a highly
sensitive H2O2 concentration-dependent degradation of POD
Fig. 1 Preparation and characterization of DFO, GOx conjugated, ATO loaded nanohybrid (D-G-PSi@POD). (A) Schematic illustration of the
construction of glucose responsive delivery system and the orchestrated cascade for diabetic wound care. The detrimental side product of H2O2,
was utilized and consumed, further aiding the close-loop system. (B) TEM/SEM images showing morphologies of (a) PSi, (b) PSi@POD and (c) their
respective EDX spectra at particle site and the background, (d) D-G-PSi@POD and (e) D-G-PSi@POD embedded on the collagen patch without obvious
morphology changes. (C) FTIR spectra of PSi, PSi@POD, D-PSi@POD and DFO, suggesting a successful encapsulation and Schiff-base formation. (D) Size,



































































































388 | Mater. Horiz., 2019, 6, 385--393 This journal is©The Royal Society of Chemistry 2019
and the mechanism was similar to those reported elsewhere.13
Briefly, POD consumes H2O2 and degrades into ODEX,
p-hydroxymethylphenol (HMP), pinacol boronate and dimethyl
boronate, as confirmed by 1H NMR (Fig. 2A(c)). TEM images
further confirmed this close-loop cascade (Fig. 2B). An inte-
grated PSi@POD structure could be observed after 24 h incuba-
tion without the addition of glucose. However, after 1 h of
incubation at 1 mg mL1 glucose concentration, the edge of the
particle became obscure upon disassembly of the nanohybrid,
as a result of H2O2 induced POD degradation. This pheno-
menon was more evident upon increasing the glucose concen-
tration to 4 mg mL1. After 24 h, the shell structure of POD
was barely visible at 4 mg mL1 glucose concentration and
at 1 mg mL1, only an indistinct polymeric layer was found.
Overall, these results suggested a glucose induced close-loop
particle degradation cascade.
To better facilitate the in vivo application of the nanohybrid,
we further embedded the particles into a collagen scaffold.
Collagen has shown good attachment/adhesion to different
type of cells and has been widely applied in wound care
applications.43 However, bare collagen hydrogel usually results
in poor stability and mechanical properties, which may restrict
the wound closure efficacy.44,45 The degradation product
of POD (ODEX) has large number of aldehyde groups, thus
it may function as a natural cross-linker during the in situ
hydrogel formation.44 To confirm our hypothesis, SEM images
of lyophilized hydrogel were first obtained. After full dispersion
and lyophilization, the morphologies of bare and particle
Fig. 2 (A) Investigation of the degradation of POD including (a) macroscopic images, showing H2O2 induced POD degradation; (b) quantitative
investigation of degradation behavior via colorimetric method; (c) 1H NMR spectrum of POD in D2O with or without addition of H2O2 confirmed the
degradation behavior of POD. (B) TEM images of D-G-PSi@POD with different concentrations of glucose at different time-points, suggesting the glucose
dependent disassembly of the nanohybrid. (C) Mechanical characterization of different hydrogels showing the in situ nanoparticle/hydrogel
transformation. Rheological dynamic oscillatory stress sweep tests of (a) C, (b) COD, (c) CP, (d) CP1, (e) CP4 and (f) the stacking figure. Solid data
points in a–f correspond to the storage modulus G0. Open data points in a- f correspond to the loss modulus G00. In f, black square, black circle, green
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embedded collagen hydrogels were observed to be different:
The pores of the latter hydrogel were smaller (Fig. S5, ESI†),
which is favorable for improving the strength of hydrogel. The
oscillatory stress sweep tests (Fig. 2C) and angular frequency
sweep tests (Fig. S6, ESI†) of different hydrogels, including bare
collagen (C), collagen + ODEX (COD), collagen + PSi@POD
(containing the same concentration of ODEX, CP), collagen +
PSi@POD + 1 mg mL1 glucose (CP1) and collagen + PSi@POD +
4 mg mL1 glucose (CP4) were performed and the corres-
ponding storage moduli (G0) and loss moduli (G00) were
recorded. Viscoelastic properties of the different hydrogels
were cumulatively characterized by the viscoelastic figure
of merit (VFOM), calculated as VFOM = |G*|tan d, where
G* = (G02 + G002)0.5 and tan d = G00/G0.46 Fig. 2C clearly suggests
a structural breakdown occurring at higher shear stress
when adding ODEX or PSi@POD, consequently, the CP4 group
showed the highest stiffness enhancement. Similar tendency
was also observed from VFOM value, where CP4 gave a value of
1668 Pa at 8 Hz compared to 322 Pa of C (Table S1, ESI†). The
reason for this enhanced viscoelastic property of CP4 compared
to COD, despite the same cross-linker concentration, is related
to the decreased local pH value caused by the synchronously
produced gluconic acid. It has been previously suggested that
insoluble collagen charges will become positive within an acidic
environment, allowing the collagen fibers to repel each other
and de-aggregate – further facilitating the interactions between
collagen and the cross-linker,47 and imparting a higher struc-
tural stiffness for the CP4 group.
We further investigated the drug loading and release profile
of D-G-PSi@POD in vitro. In this study, small molecule drugs
are chosen as model drugs since they are more attractive for
their lower product development costs and higher commercia-
lization potential. Thus, both hydrophobic (atorvastatin, ATO)
and hydrophilic (DFO) drugs were loaded in the nanohybrid.
Topical delivery of DFO can accelerate angiogenesis by promoting
the expression of hypoxia inducible factor 1a (Hif-1a) and
vascular endothelial growth factor (VEGF), which further
promote the wound healing process;48,49 while the positive
effect of ATO and DFU due to their anti-inflammatory effect
has been previously reported.50,51 Herein, the hydrophobic
drug ATO was loaded into PSi, because PSi has displayed
improvement of the in vivo drug bioavailability, especially for
hydrophobic drugs.52 The hydrophilic drug DFO was anchored
on the outer surface of the nanohybrid through dynamic
covalent bond during Schiff-base formation. The final loading
degrees of ATO and DFO were 2.4  0.2% and 4.7  0.5%,
respectively. Due to the coverage of POD layer, ATO showed
a clear H2O2 concentration dependent release. However,
maximized ATO release was achieved at relatively high H2O2
concentration, while at common physiological conditions the
drug release was barely observed (Fig. S7A, ESI†). As illustrated
above, the introduction of GOx may not only solve this problem,
but the synchronously generated gluconic acid can also decrease
the surrounding pH value and trigger the release of DFO. The
ATO/DFO release behavior from both free particles (Fig. S7B
and C, ESI†) and particles loaded collagen patch (Fig. 3A) were
Fig. 3 (A) Transwell assisted in vitro (a) ATO and (b) DFO release curves for different formulations embedded on collagen patches at different glucose
concentrations (0, 1 or 4 mg mL1) in phosphate buffer saline (PBS) within 72 h. (B) Biocompatibility studies of different components. Cell viability of
fibroblast cells at 24 h (a) and 48 h (b). Different components with series of concentrations were incubated with fibroblast cells for 24 h (a) and 48 h (b).
Concentrations indicate the amount of PSi within the system or the corresponding concentrations in D-G-PSi@POD with constant PSi concentration.
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investigated at different glucose concentrations (0, 1 and
4 mg mL1). Sustained and glucose-triggered ATO/DFO releases
were observed when the nanohybrid was employed. Only
9.5  1.4% of ATO and 35  2.9% of DFO were released after
72 h without glucose addition, whereas for free drugs loaded
collagen patch, over 97% of the drugs were released within
the first 3 h. Cumulative ATO/DFO release was significantly
higher when increasing the glucose concentration, wherein
after 72 h, the cumulative release of ATO/DFO was 57  2.7%
and 71  22%, respectively, at 1 mg mL1 glucose concen-
tration and this value increased to more than 90% at glucose
concentration of 4 mg mL1. This glucose dependent release
may further lead to stage specific, temporal drug release from
the patch. This is important as the local glucose content in
diabetic wounds is highly correlated to the diabetes condition
and tissue repairing process.36 With the closure of the dermis
gap, fewer blood and tissue exudates can infiltrate to the wound
bed, thus altering the release behavior of both drugs to benefit
the therapeutic efficiency and rehabilitation.
Biocompatibility of the different components in the nano-
system was further evaluated using fibroblast cells. After 24 and
48 h co-incubation, most of the components did not cause an
obvious decrease in cellular viability, preliminarily indicating
low cytotoxicity of the drugs and the materials (Fig. 3B). Notice-
ably, a sharp cell viability decrease was observed for the GOx
group (decreased to 1%), due to the generation of H2O2 upon
addition of GOx to the high glucose DMEM medium (4 mg mL1
glucose). However, POD particles conjugated with GOx showed a
totally reversed effect on the cytotoxicity with a cell viability of
83  2.0% at the highest concentration (48 h), suggesting in situ
close-loop H2O2 consumption.
In vitro angiogenesis was also evaluated on human umbilical
vascular cells (HUVECs) through a typical transwell facilitated
tube-formation assay. It has been previously suggested that the
angiogenesis-promoting efficacy of DFO can interfere with the
activity of prolylhydroxylases (PHDs), which is a key factor in
the degradation process of Hif-1a. This excess degradation
of Hif-1a will further promote the downstream vascular
endothelial growth factor (VEGF) expression, thus activating
the angiogenesis process.49 As can be seen in Fig. S8 (ESI†), the
HUVEC cells merely showed tubulization without the addition
of drugs after 12 h. The tube-formation efficacy of free drugs
and D-G-PSi@POD was further compared, and the HUVEC cells
cultured with free drugs were observed to show more vascular
tube formation compared with those cultured with D-G-PSi@POD
at 6 h. However, after 12 h, the HUVEC cells displayed similar
sprouting when administrated with free drugs, whereas for
D-G-PSi@POD group, longer tubules were subsequently observed.
This suggests a delayed yet sustained drug release from the
nanohybrid, thus confirming the in vitro drug release.
Streptozotocin (STZ)-induced diabetic mice with full thick-
ness wounds were used to evaluate the in vivo performance of
our system for diabetic wound closure. The mice were randomly
divided into four groups (n = 5) and topically administrated with
different samples, including (1) blank PSi@POD embedded
in collagen patch (CP), (2) free agents (ATO, DFO and GOx)
embedded in collagen patch (CF), (3) ATO and GOx loaded
PSi@POD embedded in collagen patch (PA), and (4) ATO, DFO
and GOx loaded PSi@POD embedded in collagen patch (PAD).
The administered dosage can be feasibly tuned by altering the
amount of particles within the collagen patch. Herein, we used
200 mg (corresponding to the amount of PSi) per patch for the
in vivo study, changing the patch every 3 days. A sharp debride-
ment, a standardized protocol for diabetic wound management,53
was conducted before administrating a new patch.
Images of wounds on the animals were taken at different
time intervals and the wound area was quantified by tracing its
margins and calculating percentage of new area to the original
wound size, using ImageJ software. As can be seen in Fig. 4A
and Fig. S9 (ESI†), significant lessening of wound area was
observed during the first 3 d for the PAD group, and a statistical
difference between PAD and PA suggests the positive effect of
DFO. It has previously been suggested that the angiogenesis
amelioration effect of DFO, via the activation of vascular
endothelial cell function, and early stage angiogenesis are key
factors for accelerating the healing process.35,49 Moreover, the
recovery rate was also significantly faster for PAD compared to
free drugs group (CF), which may be attributed to the sustained
release behavior of the system, as shown above. At day 6,
the wound closing ratio for PAD was 70  4.7% compared to
52 7.2% for the CF group (P o 0.01) and 44 3.9% (P o 0.01)
for the PA group. However, after the 6th day, the healing rate of
PAD group was highly impaired, whereas the closing rate of
wound area of the CF groups became faster. The retarded
healing process may be caused by the dermis development,
and thus, less tissue exudate and bleeding limited the release of
drugs from the nanosystem, whereas the release of free drugs
was not affected.
To confirm our hypothesis, full scanning hematoxylin-eosin
(H&E) staining images of different groups at day 7 (Fig. 4B) and
day 14 (Fig. S10, ESI†) were obtained and analyzed. Cross-
sectional analysis of histological wound sections allowed detec-
tion of the crawling distance of new skin tissues. Both CF and
PAD showed considerable wound closure compared to the PA
and CP groups. However, more obvious epidermis regeneration
was observed for the PAD group, suggesting the advanced
healing stage of PAD group compared to the free drugs group.
The epidermis functions as barrier to regulate the fluid content
around the wound bed, and a more intact epidermis can
restrain the blood and tissue exudate infiltration, thus, the
release of drug was thereby correlated to the healing stage.
Immunofluorescence staining for CD31 was studied to
investigate the distribution of microvessels in the regenerated
dermis near the wound bed, and the microvessel density (MVD)
was semi-quantitatively evaluated using an established protocol.35
As shown in Fig. 4C, CD31 staining was significantly increased
in the dermis treated PAD (181  33 microvessels/hot
spot) compared to the CP (30  6 microvessels/hot spot), PA
(56  31 microvessels/hot spot) and CF (128  28 microvessels/
hot spot) groups at day 7 (Fig. S11, ESI†). An overall subsided
MVD was observed at 14 d at the final healing stage.8,9,54
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the endothelial regression for PAD was more obvious, resulting
in a higher MVD of CF compared to PAD (124  25 vs. 69  25
microvessels/hot spot, respectively, *P o 0.05, Fig. S11, ESI†).
Similar tendency was also observed from immunohistochemistry
analysis of the fraction of Ki-67 expressing cells within the
granulation tissue, which indicates the existence of cellular
proliferation within the wound (Fig. S12, ESI†). Western blot
analysis also semi-quantitatively confirmed this stage specific
regeneration enhancement: For day 7, the Hif-1a expression
of PAD group was higher than that of CF, but a reversed
phenomenon was observed at day 14 (Fig. 4D and Fig. S13,
ESI†). Consequently, the production of VEGF exhibited a similar
tendency (Fig. S14, ESI†).55 Stage specific controlled drug release
is a crucial factor in regenerative medicine. For example, topical
administration of VEGF can significantly enhance the wound
healing process in diabetic mice, however, it has been shown
that the long-term expression or administration of VEGF in both
ischemic and non-ischemic tissues may cause aberrant vessels
formation and even angioma-like vascular tumors.56,57 The
application of our nanosystem can mimic the healing stage by
monitoring the implicated factor, further altering the release
content accordingly, and thereby enhancing the treatment.
One advantage of applying nanoparticles as a delivery
system is their feasibility in achieving combination therapy by
Fig. 4 (A) Digital photographs of the wounds at days 0, 6, 9, and 14 after injury, along with quantification of the wound area using ImageJ software. Error
bars in (A) indicate the SD value (n = 5). *P o 0.05 and **P o 0.01. (B) H&E stained full-thickness wound beds on days 7 suggesting the different recovery
degrees of different groups and less exudate caused by potent epidermis regeneration. Scale bars are 1 mm. (C) Immunofluorescence staining of CD31
suggesting the different angiogenesis degrees of different groups, showing the superior treatment efficacy of D-G-PSi@POD compared to the free drug
at an early stage (7 d) and the impaired augmented angiogenesis at 14 d due to the stage-specific drug release. All scale bars are 200 mm. (D) Western blot
analysis of Hif-1a at different healing stages, suggesting a mechanism for the treatment regimen and the stage-specific regeneration enhancement. Data
are shown as mean SD (n = 5), *P o 0.05. (E) Quantitative analysis of 3 major pro-inflammatory cytokines (IL-1b, IL-6, and TNF-a) within the wound bed
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simply co-loading multiple therapeutic agents into a single carrier.
However, simultaneous loading of therapeutics with different
physicochemical properties can present challenges. Herein, both
hydrophobic ATO and hydrophilic DFO were co-loaded in PSi@POD.
Despite the positive effect of DFO on angiogenesis, it was also been
shown to stimulate inflammation, however, the combination appli-
cation of statins may retard this phenomenon.58–60 To evaluate the
inflammation status of different groups, the secretion of three major
pro-inflammatory cytokines (interleukin 1b (IL-1b), interleukin 6
(IL-6) and tumor necrosis factor a (TNF-a)) within wound bed were
evaluated at day 7 (Fig. 4E) and day 14 (Fig. S15, ESI†). Both particles
involved groups (PA, PAD) showed significantly lower inflammation
response compared to free drugs group (CF), as the generated H2O2
was effectively consumed by POD. Furthermore, in spite of different
rehabilitation degrees of PA and PAD, the inflammation status of PA
was equal to or even superior than PAD, suggesting the positive
effect of ATO and the rationale of treatment regime.
Conclusions
In summary, due to the simple design and application of a PAE
containing oxidation responsive polymer, we have successfully
prepared a nanohybrid embedded collagen patch for diabetic
wound healing. The feasible combination of nanohybrid and
collagen patch integrated both the sensitive response ability
and multi-functionality of the nanohybrids and the wound
caring compliance by the collagen patch. Meanwhile, the
co-existence of these two components was necessary for
fulfilling the orchestrated cascade, including identifying spe-
cial pathological character in diabetic wound, triggered dual-
drugs release in a close-loop manner and in situ hydrogel
transformation. The collagen ark provided a framework for
the nanohybrid to exert its designed functionality without
causing unnecessary irritation, making it more suitable for
wound caring. Meanwhile, the degradation product of the
nanohybrid can prominently improve the mechanical property
of the collagen patch. More importantly, the newly developed
system showed a healing stage-specific proliferative enhance-
ment. Hence, the tissue regeneration was biomimetically
accelerated without any potent side effects. Both in vitro and
in vivo results confirmed feasibility of the proposed cascade,
and the superior treatment effect and better prognosis of this
newly developed system compared to the free drugs. Overall, the
results presented here support the development of a nanoparticle/
patch system for diabetic wound management, and potentially for
other tissue engineering applications.
Experimental
Details on the experimental procedures are provided in
the ESI.†
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